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Abstract 
 
A computational method known as the Similarity Ensemble Approach (SEA) was used to predict drug-target 
interactions for molecular scaffolds previously made in the Dittami lab. Through three different analyses of this SEA 
data, the most promising scaffolds were determined. These scaffolds will then be synthesized and the predictions 
will be validated through a biological assay. 
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Introduction 
 
The overall goal of this work is the discovery and synthesis of original molecular 
scaffolds as new pharmacological leads that can be used to develop therapeutic agents to treat a 
wide range of biological targets.  
 The Dittami group
1
 previously had uncovered a fast and efficient method for assembling 
complex multicyclic scaffolds using a photoinitiated intramolecular ylide-olefin cycloaddition 
method. The group has prepared, characterized, and published reports on a number of interesting 
scaffolds, some of which bear resemblance to the skeletal frameworks of biologically important 
natural products. To date, none of these scaffolds have been subjected to the scrutiny of 
biological testing. The group assembled a diverse array of novel compounds resulting from a 
tandem photoinitiated intramolecular ylide-olefin cycloaddition reaction. The syntheses of these 
compounds are short and efficient, often proceeding through common intermediates. More 
importantly, they are readily adaptable to the preparation of new scaffolds incorporating new 
ring systems and substituents. The majority of these products arise from photolysis of the 
corresponding aryl vinyl ether, aryl vinyl amine or aryl vinyl sulfide photo-precursors which 
incorporate either a pendant alkene or heterodipolarophile side chain. Most of this work has been 
done on either of two structural motifs: Type I or Type II photo-precursors, which differ in 
placement of the pendant dipolarophile side chain.  
 A goal of this group now is to identify the potential of these scaffolds as pharmacological 
agents. A secondary goal is to improve and expand upon the procedures we have developed for 
synthesis of these scaffolds.  
 Using a computational approach, biological targets have been predicted for these cyclic 
compounds. These targets were identified using the Similarity Ensemble Approach (SEA). SEA 
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is a statistics-based chemoinformatics approach that can be used to predict new targets for FDA-
approved small molecule drugs and pharmaceutical compounds. The basic approach, pioneered 
by the Shoichet group at the University of California, San Francisco
2
, relies on the premise that 
structurally similar molecules should exhibit similar biological activity. Thus, by comparing 
compounds to ligands which are known to bind to proteins, it should be possible to predict new 
drug-target associations. Their approach utilizes two types of fingerprinting (ECFP4 and 
Daylight) to assess structural similarity. They compared 3,365 US Food and Drug 
Administration (FDA) drugs to 65,241 ligands annotated in sets representing 246 protein targets 
from the MDL Drug Data Report (MDDR) database. Twenty-three previously unknown 
associations were found via this analysis and validated by bioassay. Therefore, SEA is promising 
for determining side-effects of existing drugs and discovery of new drugs.
 2 
The prediction of targets for and the evaluation of the biological activities of our novel 
scaffolds are part of a collaboration with the Shoichet group who used the SEA approach to 
compare our scaffolds to the ligands from the MDDR database. The results of this computational 
analysis were expressed using expectation values (E-values). Validation of these biological target 
predictions will then be performed experimentally. The predicted associations will be tested via 
biological assay under The Psychoactive Drug Screening Program (PDSP) at the University of 
North Carolina, Chapel Hill, directed by Dr. Bryan Roth. 
There are four specific aims for this project: 
Specific Aim I Submit our structures to the Shoichet group for chemoinformatics 
assessment using the similarity ensemble approach (SEA) to predict drug-target 
associations. 
Specific Aim II Synthesize the most promising molecular scaffolds and submit to the 
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Roth PDSP screens to test the predictions. In addition, in conjunction with the Roth 
group, we will do random screening of compounds against a broad cross section of G-
protein coupled receptors to see if we uncover other targets not predicted by the SEA 
analysis. 
Specific Aim III Use the bioassay data obtained to design a new round of targets for 
synthesis. These will incorporate bioisosteric replacements for suspected pharmacophores 
in the molecule to enhance therapeutic activity. New scaffolds will be submitted for 
additional screening against more specific targets as appropriate. 
Specific Aim IV Evaluate new procedures to enhance the depth and breadth of the 
Photoinitiated Intramolecular Ylide-Olefin Addition Reaction for synthesis of new and 
novel pharmacophore scaffolds. 
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Project Background 
 
Scaffold Syntheses 
Our group has assembled a diverse array of novel compounds resulting from a tandem 
photoinitiated intramolecular ylide-olefin cycloaddition reaction. The syntheses of these 
compounds are short and efficient often proceeding through common intermediates. More 
importantly, they are readily adaptable to the preparation of new scaffolds incorporating new 
ring systems and substituents. Our goal now is to select and resynthesize a representative cross 
section of these compounds for biological testing.  
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Figure 1: Representation of the molecular scaffolds created using photoinitiated intramolecular ylide-olefin cycloaddition 
with assigned code names (e.g. ONBE) 
 
Since we have previously made and characterized every structure shown, we are assured 
success in gaining access to samples for testing. Figure 1 shows a representative set of the kinds 
of products we have made.  
As noted earlier, the majority of these products arise from photolysis of the 
corresponding aryl vinyl ether, aryl vinyl amine or aryl vinyl sulfide photoprecursors which 
12 
 
O O
O
O
O
O
O
O
S
O
O
O
O
OEt
O
O
O
S
1. RMgBr
2. H3O
+
H2O2, NaOHR =
R =
H2O2, NaOH
1. ArS-
2. AcOH, 65 °C  
3. Ph3P=CHCO2Et
1. RMgBr
2. H3O
+
36
1 2 3
4 5 6
Type I Photoprecursors
EtO2C
Ar =2- napthyl
ArS-
OH
EtO OEt
O
OH
MgBr
NH4Cl(aq)
OH
HO
O
O
I2/HgO
EtO
OEt
O
HO
O
O
AcO
O
1.
1. KH(Cat.), DMPU
2.
10% p-TsOH
2.
pyridine/Ac2O
(49%)
(57%) (>99%)
1. 9-BBN, r.t.
PdCl2(dppf)
NaOH(aq), THF
(50%)
7 8
9
10
11 12 13 14
Type II Photoprecursor
OH OH
I
incorporate either a pendant alkene or heterodipolarophile side chain. Most of our work has been 
done on either of two structural motifs: Type I or Type II photoprecursors, which differ in 
placement of the pendant dipolarophile side chain. The synthesis of each type is shown in Figure 
2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Synthesis of Type I and Type II photoprecursors from which the scaffolds were derived 
Via the aforementioned routes we can assemble photoprecursors with a multitude of aromatic 
groups and pendant dipolarophiles, as shown in Figure 3. 
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Some examples of scaffolds resulting from the photolysis of these systems which incorporate 
features of natural products are shown in Figure 4. Notably morphine is an important analgesic 
and the huperzine alkaloids have been heralded as important acetylcholinesterase inhibitors with 
potential for treatment of Alzheimer’s and Myasthenia Gravis.  
Figure 3: Aromatic groups that were utilized in the synthesis of the scaffolds 
Figure 4: Examples of synthesized scaffolds which share similarity with naural products 
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In addition to changes in the aromatic component, there are several functional group 
transformations that are readily employed to convert our photoproducts into more diversely 
substituted products. These include reactions at the carbonyl center, carboxylic acid ester 
conversions and reactions at the alkene center. Examples can be seen in Figure 5: products like 
21 are readily converted to either the alcohol or lactone while products like 23 are easily 
modified via electrophilic addition, and products such as 22 and 24 should be readily converted 
to the angularly substituted 6,5 ring system by reductive cleavage. 
 
 Using these photoprecursors, 40 scaffolds were synthesized and the structure verified by 
NMR, and in some cases, X-ray crystallography. The structures of these scaffolds were sent as 
“SMILES” files with assigned code names (e.g. ONBE, see Figure 1) to the Shoichet group in 
San Francisco for analysis using the SEA program. SMILES, or Simplified Molecular Input Line 
Entry System, is a form of line notation used to define a molecule. Instead of using numbers, 
however, it uses a predefined code of strings in order to easily and quickly describe complex 
molecules.
3 
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Figure 5: Examples of various functional group transformations that were performed 
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SEA Data Analysis 
 
Molecular Fingerprints 
As stated earlier, the Similarity Ensemble Approach (SEA) was utilized to assess the 
structural similarity of our scaffolds to ligands known to bind to a diverse array of proteins. To 
do so, these compounds were compared using what are known as molecular fingerprints. 
Molecular fingerprints are representations of chemical structures that are useful for similarity 
searching, clustering, and classification. There are numerous fingerprinting models which 
concentrate on different aspects of chemical structures such as connectivity or topology. This 
concept is best described in comparison to a person’s fingerprint. Every person has a 
characteristic fingerprint, yet fingerprints by themselves have no other meaning. 
The most popular connectivity fingerprint algorithm is available through Daylight 
Chemical Information Systems
4
 and is referred to as Daylight and is the next evolution from 
structural keys. Structural keys were the first type of screen used for high-speed screening of 
chemical databases. These structural keys are represented by Boolean arrays, arrays in which the 
presence or absence of specific structural patterns are identified in a true/false pattern.
4
 The 
problem with the structural keys was that they were extremely specific. This specificity would 
screen out many chemicals that may have proved useful and generated many “false hits.”  The 
Daylight fingerprint algorithm addresses the lack of generality within the structural keys by 
eliminating the idea of pre-defined patterns. Daylight examines chemical structures and is able to 
identify patterns of the chemical, however the meaning of the patterns are not well defined. This 
allows for the patterns of each chemical to be compared to the patterns of other molecules to 
check for structural similarity without prioritization.  
16 
 
While the Daylight algorithm has been used in both high throughput screening and 
similarity searching methodology for decades, another method which examines the chemical 
topology fingerprints has become popular in the last few years. Specifically, the extended 
connectivity fingerprints (ECFP) are a novel class of topological fingerprints developed for 
structure-activity modeling.
5
 These fingerprints use atom information obtained from the Daylight 
atomic invariants rule to identify atoms. The atomic invariants rule are six innate properties 
which are not dependent on the fashion in which the atoms of the chemical are numbered. These 
properties are:  
o The number of immediate neighbors that are “heavy” (non-hydrogen) atoms 
o The valence minus the number of hydrogens  
o The atomic number 
o The atomic mass 
o The atomic charge 
o  The number of attached hydrogens.
5
 
Often the additional property of whether the atom is connected to at least one ring is included. 
However, a novel feature of this ECFP fingerprint is that is does not follow a linear pathway like 
Daylight but uses a series of circular bond lengths to capture the environment of an atom in a 
pattern. This is reflected in the naming of these ECFP fingerprints. Each name is followed by a 
number which is the effective diameter of the largest structural feature and is equal to twice the 
number of iterations performed. For instance, ECFP4 indicates that two iterations were 
performed and the largest possible fragment will have a width of four bonds while ECFP6 
indicates that three iterations were performed producing the largest possible fragment with six 
17 
 
bond widths. A second novel feature is that a pre-defined number of iterations are performed as 
opposed to continuously defining unique patterns. This allows the ECFP patterns to contain both 
positive and negative structural information crucial for analyzing molecular activity.  
 Each chemical structure receives a unique score for both the Daylight and ECFP 
fingerprint based on the atomic invariants rule. For Daylight these properties are linear and for 
ECFP they are circular. In order to suggest similarity between two compounds, the fingerprint 
scores, which range from zero to one, must be similar.  
 
E-Values 
 Similarity between fingerprint scores is made statistically significant by expected values 
(E-values). This parameter describes the number of hits one can expect to see by chance when 
searching a database of a particular size; essentially describing the background noise. For 
example, an E-value score of one assigned to a hit can be interpreted as meaning that in a 
database it is expected to see a single match with a similar score by chance. The closer to zero 
the E-value is, the more significant the match between fingerprint scores. Any match with an E-
value less than 1x10
-10
 is considered significant and suggests that the match is not likely to be 
occurring by chance.
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Drugability  
 
 In addition to the structural similarity, we also decided to analyze the chemophysical 
properties of the molecules to establish if there was a connection between our compounds and 
ligand sets in terms of these physical properties. These properties (such as ClogP, ClogD, and 
Topological Polar Surface Area) can be used as predictors for biological activity of compounds. 
18 
 
This composite data can provide information about a compound’s “drugability” or tendency to 
interact with biological targets. 
 Among the values that are useful for calculating the drugability of a compound are 
ClogP, ClogD7.4, and the Topological Polar Surface Area. Log P, also known as the partition 
coefficient, is defined as the log of the ratio of a compound in n-octanol to its concentration in 
water. This value is a measure of how hydrophilic a compound is and also how well a compound 
would absorb in the body. Higher Log P values correlate to lower absorption, which is important 
when designing medicinal compounds.
7
 ClogP is a method of quickly calculating Log P, which 
breaks the compound into fragments and calculates the fragment values based on the bonding 
environment.
8
 
While Log P is calculated for compounds when they are neutral, Log D, or the 
distribution coefficient, uses the same calculation, except it includes both the neutral and charged 
forms of the compound. If the compound is neutral, then the Log P equals the Log D; however, 
when the molecule is charged, the degree to which it partitions itself in octanol may differ. Log 
D varies with pH, so for drugability, the Log D that is often used is at physiological pH, which is 
7.4.
9
 ClogD uses the same algorithm as ClogP. 
Topological Polar Surface Area (TPSA) is calculated by adding the contributions of the 
polar fragments on the surface of a compound.
10
 This differs from Polar Surface Area, which 
involves optimizing the geometry and creating a 3D molecule, and therefore takes longer 
amounts of time to calculate.
11
 TPSA relates to how well a molecule transports across 
membranes, and is important when considering oral bioavailability.
12 
This value is also 
especially useful regarding intestinal absorption and crossing of the blood-brain barrier. It has 
19 
 
been found that drugs with TPSAs less than 60 Å
2 
are absorbed more than 90% in the intestines 
while drugs with TPSAs greater than 140 Å
 2
 are absorbed less than 10%.
13 
Lipinski’s “Rule of 5” was developed to determine if compounds with medicinal 
properties would be good orally active drugs. The rule states that poor absorption of drugs is 
more likely when there are more than 5 hydrogen bond donors (OHs or NHs), there are more 
than 10 hydrogen bond acceptors (nitrogen or oxygen atoms), the molecular weight is greater 
than 500 daltons, and the Log P is greater than 5.
14
 This means that drugs with good oral activity 
are smaller and more hydrophilic than non-orally active drugs.
15
 These rules were determined by 
calculating values for drugs in clinical Phase II with good permeability and absorption. While 
most medicinal compounds obey the rule, there are a few classes of orally active drugs which do 
not fit within these guidelines, which include antibiotics, antifungals, vitamins and cardiac 
glycosides.
14
 Recently, there have been extensions to the rule, with one paper by Ghose et al. 
stating that good absorption is more likely when the Log P is between -0.4 and 5.6, the molecular 
weight is between 160 and 480 daltons, the molar refractivity is between 40 and 130 and the 
number of atoms is between 20 and 70.
16
 A separate paper by Oprea et al. says that there is good 
absorption when the Log P is between -3.5 and 4.5, the Log D at pH 7.4 is between -4 and 4, 
there are no more than 10 non-terminal single bonds, there are no more than 8 hydrogen bond 
acceptors and there are no more than 4 rings.
15 
 
  
20 
 
Data Analysis Methodology  
 
 The compounds synthesized by the Dittami groups were submitted to Michael Keiser of 
the Shoichet group as “SMILES” files with corresponding codenames (e.g. ONBE, see Figure 1). 
These compounds were then analyzed by both the Daylight and ECFP4 fingerprinting methods 
as a part of the Similarity Ensemble Approach. This data was posted to online databases. 
Two separate yet simultaneous approaches were taken to analyze the data. The first 
approach used the E-values to obtain an initial group of compounds for which drugability data 
was independently calculated and these values used to create a separate “hit” list. The second 
approach focused on the promiscuity of the proteins and compounds and the E-Values of the 
synthesized compounds. These lists were then cross-referenced to provide a master “hit” list of 
the compounds which will undergo biological testing.  
Typically, there is not a single strict threshold that is used for deciding which E-values 
are significant. In their Nature paper, Keiser used a 1x10
-10
 threshold as a rough cutoff. However, 
according to Keiser, typically E-values smaller than 1x10
-5
 are used in practice.  For the purposes 
of this data analysis, E-values of 1x10
-7
 or smaller were considered. 
As stated previously, each of our scaffolds was compared to ligand sets for a diverse 
array of proteins. Within the online database, for each predicted protein-scaffold interaction, the 
ligands were ranked by either an ECFP4 or Daylight value, depending on which database it 
occurred in. This value, the Tanimoto coefficient (Tc), was between 0 and 1, with 0 being 
dissimilar compounds based on fingerprinting results and 1 being identical compounds.
17
 
 The data comparing the scaffolds to known biological targets were split into two 
databases based on which fingerprinting method was used for the comparison – Daylight or 
ECFP4. The data from this analysis was transferred into a spreadsheet and sorted by E-values. 
21 
 
Any compound with a significant E-value, less than 1x10
-7
, was selected for further analysis 
(Figure 6).  
 
Figure 6: Screenshot of Daylight fingerprint results sorted by decreasing E-Value in context of the biological target 
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SEA and Drugability Analysis 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 Figure 7: Flowchart of Drugability Analysis 
Both the Daylight and ECFP4 databases were separately examined for the drugability 
analysis. When looking at the data in a database, we sorted the biological targets by E-value 
(Figure 7). E-values with an exponent of 1x10
-7
 or lower were considered to be good matches 
and were the only matches considered from that point forward.  
For every predicted protein-scaffold interaction, the set of known ligands associated with 
the target were examined and analyzed (Figure 8).  All of the ligands shown were examined and 
were subsequently sorted (targets in the ECFP4 database were sorted according to ECFP4 value 
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and target in the Daylight database were sorted according to Daylight value). Once these ligands 
were sorted by their respective comparison value, a cut-off value was established to narrow 
down the list of ligands to no more than the top twenty ligands (sorted by ECFP4 or Daylight 
value). The cut-off values were between 0.4-0.5 for Daylight and 0.1-0.2 for ECFP4.  
 
 
 
 
 
 
 
Figure 8: Screenshot of the top ranked known ligands for the Peroxisome proliferator-activated receptor alpha target 
protein used for comparison to scaffolds 
A number of calculations were then performed on the selected ligands. These calculations 
included the ClogP, ClogD at pH 7.4, TPSA (Topological Polar Surface Area), TPSA at pH 7.4, 
Molecular Weight, HBD (Hydrogen Bond Donors), and HBD at 7.4, and pKa. 
The calculations for every ligand in a set were compared to the calculations of its 
associated scaffold. Ligands whose ClogP and ClogD values were within 1-2 and whose TPSA 
value was within 10 of the scaffolds were chosen as the best matches for biological testing.  
 
 
Promiscuity and E-Value Analysis 
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Figure 9: Flowchart of Promiscuity and E-Value Analysis  
 
To compare the most promiscuous proteins and synthesized compounds (Figure 9), a new 
spreadsheet was created with all the predicted protein-scaffold interactions with an E-value with 
an exponent of 1x10
-7
 or less. Data from the Daylight database and ECFP4 database were 
considered separately. For each predicted interaction, the protein code, the protein name, the 
synthesized compound code, and its E-value were recorded.  
Proteins that were predicted to interact with multiple scaffolds with very low E-values 
were recorded. Similarly, scaffolds that were predicted to interact with multiple proteins 
(especially those that were predicted to interact with multiple similar proteins) with very low E-
values were recorded. Scaffolds that were only predicted to interact with one protein but had 
extremely low E-values were also considered and recorded.  
 
      
Promiscuity and E-Value Analysis 
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-7
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Results 
 
SEA and Drugability Analysis 
Based on the drugability data, the following scaffolds were determined to be the best 
matches to the ligand sets of certain proteins:  
 
Table 1: Best Scaffolds Based on Drugability Analysis 
Compound Name Protein Name E-value Database 
ONBE NAD-dependent histone deacetylase SIR2 3.81x10
-19 
ECFP4 
ONKA NAD-dependent histone deacetylase SIR2 2.57x10
-15 
ECFP4 
OpMKA Delta opioid receptor  6.08x10
-8 
Daylight 
ONEM1 Estradiol 17-beta-dehydrogenase 1 6.05x10
-8 
Daylight 
OdMED Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 1.53x10
-16 
Daylight 
ONAM DNA polymerase alpha subunit 6.42x10
-14 
Daylight 
ONEM1 DNA polymerase alpha subunit 9.27x10
-12 
Daylight 
OpMKA Kappa opioid receptor 2.86x10
-12 
Daylight 
OpMKA NADH-ubiquinone oxidoreductase chain 4 1.48x10
-9 
Daylight 
OmMAA1 NADH-ubiquinone oxidoreductase chain 4 1.68x10
-9 
Daylight 
OdMAA NADH-ubiquinone oxidoreductase chain 4 7.40x10
-10 
Daylight 
OpMKA Mu opioid receptor (OPRM_CAVPO) 1.74x10
-7 
Daylight 
OpMKA Mu opioid receptor (OPRM_HUMAN) 2.33x10
-7 
Daylight 
 
Promiscuity and E-Value Analysis 
In the Daylight database, 28 proteins had predicted interactions with scaffolds with E-values 
with an exponent of 1x10
-7
 or less. A total of 60 predicted protein-scaffold interactions had an E-
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value with an exponent of 1x10
-7
 or less. Of all the listed proteins, seven proteins were chosen 
because they had the most predicted protein-scaffold interactions with the lowest E-values. 
These proteins were: 
 Peroxisome proliferator-activated receptor alpha 
 Glutamate-gated chloride channel 52.5 kD 
 Glutamate-gated chloride channel 49.8 kD 
 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 
 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
 Quinone oxidoreductase  
 NADH-ubiquinone oxidoreductase chain 4  
Table 2: Proteins with high promiscuity and low E-Values in the Daylight database 
Protein Name Number of 
Interactions 
Lowest E-
Value 
Peroxisome proliferator-activated receptor alpha  9 2.41x10
-44 
Glutamate-gated chloride channel 52.5 kD  4 1.09x10
-35 
Glutamate-gated chloride channel 49.8 kD  4 1.09x10
-35 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 
1 
 3 4.99x10
-31 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 
2 
 3 1.7x10
-26 
Quinone oxidoreductase   3 5.14x10
-25 
NADH-ubiquinone oxidoreductase chain 4   4 7.04x10
-10 
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A number of synthesized compounds were selected because of their promiscuity or 
because they had a predicted protein-scaffold interaction with a low E-value. Compounds with 
high promiscuity are shown in the table below. 
 
Table 3: Compounds with high promiscuity and low E-Values in the Daylight database 
Compound Name Number of Interactions Lowest E-Value 
OmMED 2 2.50x10
-21 
OdMED 6 5.14x10
-25 
ONAM 8 1.06x10
-15 
ONEM1 7 3.89x10
-40 
OpMEM2 5 1.09x10
-35 
OpMKA 8 2.41x10
-44 
 
Compounds with a predicted protein interaction with a low E-value are shown below. 
Table 4: Compounds with low E-Values in the Daylight database 
Compound Name E-Value 
OdMAA 5.74x10
-39 
OmMAA1 5.73x10
-40 
OmMAA2 4.79x10
-39 
ONBE 7.71x10
-39 
ONEE 1.01x10
-36 
ONKA 8.70x10
-40 
OPBE 1.10x10
-39 
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In the ECFP4 database, three proteins had predicted protein-scaffold interactions with E-
values with an exponent of 1x10
-7
 or less. A total of seven predicted interactions had an E-value 
with an exponent of 1x10
-7
 or less. Of all the listed proteins, one protein was chosen because it 
had the most predicted protein-scaffold interactions with the lowest E-values. This protein was: 
 NAD-dependent histone deacetylase SIR2  
Table 5: Proteins with high promiscuity and low E-Values in the ECFP4 database 
Protein Name Number of Interactions Lowest E-Value 
NAD-dependent histone deacetylase SIR2  4 3.81x10
-19 
 
No compounds in this list were part of more than one predicted protein-scaffold interaction. 
Only two drug-target interactions appeared as predicted protein-scaffold interactions in 
both databases. These are ONEM2 for Aldo-keto-reductase family 1 member C3 and ONAM for 
NAD-dependent histone deacetylase SIR2. Both of these predicted interactions had relatively 
high E-values though, with exponents >   1x10
-9
. This is noteworthy; that with so many predicted 
protein-scaffold interactions, only two appear in both databases and neither of them are 
particularly good matches.  
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Conclusions 
 
After analyzing the predicted protein-scaffold interactions based on drugability, E-value 
and promiscuity, the following four scaffolds were chosen as the most promising.  
 
ONEM1 
 
OpMKA 
 
ONAM 
 
OdMED 
 
Figure 10: Structures of the best scaffolds 
 In addition, the following proteins were chosen as the best targets based on E-value, 
promiscuity and protein function analysis: Aldo-keto-reductase family 1 member C3, due to its 
possible role in asthma and cell growth,
18 
and Sarcoplasmic/endoplasmic reticulum calcium 
ATPases 1 and 2, due to their potentials as therapeutics for heart failure. 
19, 20 
It is recommended that the previous four scaffolds be synthesized and the protein-
scaffold predictions be validated via biological assay, with the most interesting protein targets. 
Once the scaffolds have been confirmed to bind to the targets, new derivatives should be 
synthesized and investigated as potential drugs.  
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